Publications Database

Lindsay R. L. et al. (2006)

Dietary status and impact of risperidone on nutritional balance in children with autism: A pilot study.

Journal of Intellectual and Developmental Disability

December, 31(4), pp. 204-209.

Read Abstract (New Window)

Lord C. et al. (2005)

Challenges in evaluating psychosocial interventions for autistic spectrum disorders.

Journal of Autism and Developmental Disorders

35(6), pp. 695-708

Read Abstract (New Window)

Marcus R. N. et al. (2009)

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

48(11), pp. 1110-1119

Read Abstract (New Window)

Marcus R. N. et al. (2011)

Aripiprazole in the treatment of irritability in pediatric patients (aged 6-17 years) with autistic disorder: results from a 52-week, open-label study.

Journal of Child and Adolescent Psychopharmacology

21(3), pp. 229-236

Read Abstract (New Window)

Martin A. et al. (2004)

Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.

American Journal of Psychiatry

161(6), pp. 1125-1127

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2014)

Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders.

Pharmacogenomics

14(3), pp. 295-302.

Read Abstract (New Window) Read Full (New Window)

McCracken J. T. et al. (2002)

Risperidone in children with autism and serious behavioral problems.

New England Journal of Medicine

347(5), pp. 314-321

Read Abstract (New Window) Read Full (New Window)

McDougle C. J. et al. (2000)

Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone.

Child and Adolescent Psychiatric Clinics of North America

January, 9(1), pp. 201-224.

Read Abstract (New Window)

McDougle C. J. et al. (2005)

Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology.

American Journal of Psychiatry

162(6), pp. 1142-1148

Read Abstract (New Window) Read Full (New Window)

Nikolov R. N. et al. (2009)

Gastrointestinal symptoms in a sample of children with pervasive developmental disorders.

Journal of Autism and Developmental Disorders

39(3), pp. 405-413

Read Abstract (New Window)

Pearson D. A. et al. (2013)

Effects of extended release methylphenidate treatment on ratings of attention-deficit hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms.

Journal of Child and Adolescent Psychopharmacology

23(5), pp. 337-351.

Read Abstract (New Window) Read Full (New Window)

Posey D. J. et al. (2007)

Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures.

Biological Psychiatry

61(4), pp. 538-544.

Read Full (New Window)

Scahill L. et al. (2006)

A prospective open trial of guanfacine in children with pervasive developmental disorders.

Journal of Child and Adolescent Psychopharmacology

16(5), pp. 589-598.

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2016)

Effect of parent training on adaptive behavior in children with autism spectrum disorder and disruptive behavior: results of a randomized trial.

Journal of the American Academy of Child and Adolescent Psychiatry

July, 55(7), pp. 602-609.

Read Abstract (New Window)

Scahill L. et al. (2012)

Effects of risperidone and parent training on adaptive functioning in children with pervasive developmental disorders and serious behavioral problems.

Journal of the American Academy of Child and Adolescent Psychiatry

51(2), pp. 136-146

Read Abstract (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

11(4), pp. 377-388

Read Abstract (New Window)

Scahill L. et al. (2001)

Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism.

Journal of Child and Adolescent Psychopharmacology

Winter, 11(4), pp, 377-88.

Read Abstract (New Window)

Scahill L. et al. (2017)

Using a patient-centered outcome measure to test methylphenidate versus placebo in children with autism spectrum disorder.

Journal of Child and Adolescent Psychopharmacology

March, 27(2), pp. 125-131.

Read Abstract (New Window) Read Full (New Window)

Scahill L. et al. (2016)

Weight gain and metabolic consequences of risperidone in young children with autism spectrum disorder.

Journal of the American Academy of Child and Adolescent Psychiatry

May, 55(5), pp. 415-423.

Read Abstract (New Window)

Smith T. et al. (2016)

Atomoxetine and parent training for children with autism and attention-deficit-hyperactivity disorder: A 24-week extension study.

Journal of the Canadian Academy of Child and Adolescent Psychiatry

October, 55(10),

Read Abstract (New Window)